Trial Search Results
Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Provide patients with serious AdV infection or disease access to treatment with BCV.
Stanford is currently not accepting patients for this trial.
- Drug: Brincidofovir
- Confirmed serious AdV infection based on clinical symptoms and laboratory testing
showing AdV in the blood or other bodily fluids
- Able to swallow medication, either tablet or liquid
- Previous dosing with Brincidofovir
- If female, not pregnant or trying to become pregnant
Ages Eligible for Study
2 Months - N/A
Genders Eligible for Study